TY  - JOUR

T1  - Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results.

JO  - Journal of Clinical Oncology

PY  - 2019/05/20

AU  - Hussain SA

AU  - Maroto P

AU  - Climent MÁ

AU  - Bianchini D

AU  - Jones RH

AU  - Lin C-C

AU  - Wang S-S

AU  - Dean E

AU  - Crossley K

AU  - Schlieker L

AU  - Bogenrieder T et al

ED  - 

DO  - DOI: 10.1200/jco.2019.37.15_suppl.5030

PB  - American Society of Clinical Oncology (ASCO)

VL  - 37

IS  - 15_suppl

SP  - 5030

EP  - 5030

Y2  - 2024/12/22

ER  -